Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Weight Gain Trajectory: early-phase trial registry
2 of 4 indexed Weight Gain Trajectory trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Weight Gain Trajectory: 4 US clinical trials tracked, 2 recruiting.
Weight Gain Trajectory is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Response Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition weight-gain-trajectory
OPEN 2 | RECR 50% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Weight Gain Trajectory lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Weight Gain Trajectory on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Weight Gain Trajectory is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
Children's Hospital Medical Center, Cincinnati
NCT06028113
Assessing Better Bottles for Babies
Duke University
NCT06357299
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
Response Pharmaceuticals
NCT06640972
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
Baylor University
NCT04498455
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Weight Gain Trajectory records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Weight Gain Trajectory trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Weight Gain Trajectory page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Weight Gain Trajectory trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Response Pharmaceuticals sponsors the most Weight Gain Trajectory trials on record, review their full trial history before evaluating a specific study. See Response Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Weight Gain Trajectory condition card totals 4 registered trials; most-linked intervention Prebiotin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.